研究单位：[1]Peking University People's Hospital[2]Ascentage Pharma Group Inc.[3]HealthQuest Pharma Inc.[4]Peking University People's Hospital,Beijing,Beijing,China,100044[5]Sun Yat-sen University Cancer Center,Guangzhou,Gongdong,China[6]Nanfang hospital of southern medical university,Guangzhou,Guangdong,China,510515[7]Shenzhen Second People's Hospital,Shenzhen,Guangdong,China[8]The First affiliated hospital of Guangxi Medical University,Nanning,Guangxi,China[9]Henan Provincial Oncology Hospital,Zhengzhou,Henan,China,450003[10]Henan Provincial people's Hospital,Zhengzhou,Henan,China[11]Tongji Hospital medical college Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[12]Union Hospital medical college Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[13]Zhongnan Hospital of Wuhan University,Wuhan,Hubei,China[14]Xiangya Hospital Central South University,Changsha,Hunan,China[15]Jiangsu Province Hospital,Nanjing,Jiangsu,China[16]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China[17]The First affiliated hospital of Nanchang University,Nanchang,Jiangxi,China[18]First Hospital of Jilin University,Changchun,Jilin,China[19]The Affiliated hospital of Qingdao University,Qingdao,Shandong,China[20]Qilu hospital of Shandong University,Jinan,Shangdong,China[21]Ruijing Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,Shanghai,China,200032[22]West China Hospital of Sichuan University,Chengdu,Sichuan,China[23]Blood Diseases Hospital Chinese Academy of Medical Sciences,Tianjin,Tianjin,China[24]The First Affiliated Hospital, Zhejiang University School of Medicine(hematology dept),Hangzhou,Zhejiang,China[25]The First Affiliated Hospital, Zhejiang University School of Medicine(HSCTdept),Hangzhou,Zhejiang,China
The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors. The efficacy of HQP1351 is determined by evaluating the subjects' event free survival (EFS).
